





For INVESTORS Only

**CONNECTPRENEUR
INVESTOR MEETING**



**May 28, 2026
11am - 12pm ET**



**Curated presenters.
Investors only.**

CONNECTpreneur.org

AGENDA

11:00 - 11:05 AM

MEETING OPENS & INTRODUCTIONS

- TIEN WONG, Founder and Host, CONNECTpreneur Community

11:05 - 12:00 PM

PITCH SESSIONS + Q&A

Companies will be introduced by:

TIEN WONG, Founder and Host, CONNECTpreneur Community

Q&A hosted by:

AVERY NORTH, Assistant Community Manager, CONNECTpreneur

PRESENTING COMPANIES



æther
THERAPEUTICS

Aetherthx - Aaron Schuchart



alleviate

Alleviate Therapy - Alain Tranchemontagne



BioBond
POWERED BY NATURE

BioBond - Marc McConnaughey

C2RE

C2RE - Daniel Wood



Hedonia™

Hedonia USA - Gary Schwartz



ODNASS
ONCOGENIC DNA SCREENING SYSTEM

Odnass - Velimir Pajic



Wintermute
Biomedical

Wintermute Biomedical - Thomas Rau

AETHER THERAPEUTICS

Breaking the Chains of Opioid Addiction

FUNDING TO DATE

\$7 Million

\$5M in grants

CURRENT RAISE

\$10M Convertible Note

\$6M committed · Lead investor secured

STAGE

Phase 1/2 Clinical Studies

VALUE INFLECTION

Human Proof of Principle

COPT patients · Within 2.5 years

EXIT TIMELINE

Potential exit < 3 years

10X+ return potential

CONTACT

Aaron Schuchart, MBA

President & CEO

aaron@aetherthx.com

Aether Therapeutics

ADDRESSING THE GLOBAL OPIOID CRISIS BY TARGETING THE MOLECULAR CAUSE OF DEPENDENCE

The Problem

Over 80 million Americans use opioids for chronic pain (COPT), yet no approved therapy eliminates the risk of dependence. The opioid crisis demands a novel solution targeting the root molecular cause — not just the symptoms.

ATX-1209 (LD 6 β N)

A novel, once-daily oral addiction modulator that binds to the mu opioid receptor (MOR), gradually reversing receptor adaptation — **suppressing dependence signals while fully preserving analgesic benefit.**

Chronic Pain (COPT)

Opioid Use Disorder

Neonatal OUD (NOWS)

EVIDENCE PACKAGE

DOMAIN	STATUS
Efficacy	Consistent results across multiple nonclinical pain, dependence, drug-seeking & hyperalgesia models in multiple species; proof of mechanism demonstrated in opioid-treated patients
Safety	Clean two-species toxicology (oral formulation); human safety confirmed in prior Phase 1 at doses exceeding planned studies
Stage	Phase 1/2 clinical studies — clinical objective: reduced dependence in COPT patients without change in analgesic benefit

INVESTMENT HIGHLIGHTS

\$10M

CURRENT RAISE

Convertible note · \$6M committed

10X+

RETURN POTENTIAL

Lilly/SiteOne, Latigo Series B (2025)

< 3 Yrs

EXIT TIMELINE

Early exit or continued value creation

LEADERSHIP TEAM

NAME	ROLE	BACKGROUND
Aaron Schuchart, MBA	President & CEO	30 years; Amgen, Novartis, Coherus; C-suite at two public biotechs; multiple capital raises & strategic transactions
Wolfgang Sadee, PhD	Co-founder, CSO	Professor OSU/UCSF; >400 publications; top 0.05% cited scholar
Bruce Imbert, MD, PhD	CMO & Head of R&D	20+ years clinical development & regulatory; Indivior, TemperoBio, Pear Therapeutics; lead clinician for Sublocade & Opvee
Laurence Nore, MBA	Fractional COO	25+ years ops/BD leadership; Amgen, Roche
Rick Hawkins	Co-founder, Chairman	Founded & sold Pharmaco, Sensus, Covance, Lumos; 40-year biotech veteran

Product profile projected based on published non-clinical studies. Valuation benchmarks: Lilly/SiteOne; Latigo Biosciences Series B, 2025.

FOR INFORMATION PURPOSES ONLY • NOT A SOLICITATION



Who we are

Alleviate is a commercial entity that delivered \$741k in 2025, a gross profit margin of 68%, and an EBITDA loss of <\$644k>. Our products treat chronic musculoskeletal soft tissue injuries at home, either as an adjunct to, or a replacement for physical therapy at a fraction of the cost. Our mission is to help millions of people avoid surgery.

The problem

Today, someone who suffers from an acute soft tissue injury approaches the problem as follows.



As a result, their injury has commonly become chronic by the time they seek assistance of a healthcare provider. Chronic injuries are difficult to resolve with conservative care because of 3 problems.

- Time: chronic injuries are slow to resolve, undermining patient motivation, at PT is time-consuming.
- Expenses: the cost of early trial and error and physical therapy results in patients ‘quitting’ before they resolve.
- Motivation: patient compliance, driven by loss of motivation, is cited as the primary cause of failed resolution.

The Alleviate solution

Alleviate addresses these problems by building on the evidence behind the benefits of Instrument Assisted Soft Tissue Mobilization (IASTM) and Physical Therapy combined. Results speak for themselves:

- 85% of patients who use the system 10 minutes a day, 3+ days a week achieve significant pain reduction.
- 20% pain reduction at week 1, up to 70% at 6 weeks on average.
- The solution costs a fraction of PT, ignoring other products used.
- The app motivates, ensures proper use, and collects patient reported outcomes (PROMs) in the convenience of the home.

What we seek

We are looking to raise \$1.9 million to develop a scalable commercial model focused on the physician channel. It will extend our reach into the market and deliver the synergies that exist with the consumer channel already in place.

Leadership bio

Alain Tranchemontagne has over 30 years of medical device experience spanning start-ups to Fortune 500 organizations. The last 18 years have been invested in orthopedics, first with Smith & Nephew, then as President & CEO at HydroCision where he helped the organization grow 5x, and now as President & CEO at Alleviate. It’s worth noting that this experience has led him from the most invasive form of orthopedic surgery to minimally invasive procedures, and now to conservative care, essentially avoiding surgery altogether. It parallels the trends observed in the market.

The Alleviate Method

Adapting the gold standard of physical therapy for at-home use, the Alleviate Method combines three treatment modalities that work together to resolve the root causes of pain.



Our Mission

BioBond is accelerating the shift in the **\$190B coatings and adhesives sector** from petroleum-based products to a safer, sustainable, and circular future—eliminating microplastics and forever chemicals while reducing CO₂ emissions through a **capital-efficient execution model**.

Problem to Solve

Global industries from construction to automotive use **110B lbs** of petroleum-based adhesives and coatings each year, releasing **330B lbs of CO₂** along with VOCs, PFAS, microplastics, and other pollutants.

BioBond's Advantage




- “**Good-better-best**” strategy accelerates plant-based products to market
- Developed, scaled, and introduced **8 coating and adhesive products** in one year
- Products **meet or exceed competitor performance and cost**, independently certified
- Revenue from products, formulations, and intermediates at **45% margins**
- USA-made**: better price, better performance, better for everyone

Market Traction

- Alpha sites in antimicrobial coatings covering **50,000+ sq ft**
- MOU with Korea's 3rd-largest paint company
- MOU with major Korean film laminator in the **\$15B adhesive market**
- Distributor in Mexico engaged and placing orders
- Wood lamination trials underway in the woodworking market
- Biobased hot melt prototypes ready for **\$9B packaging, tape, and personal care markets**

Patented & Tested Technology from a World-Class Team

125 years of combined experience in lab-to-market execution, scale-up, and startup operations. Recognized among the **Top Twenty Startups in Indiana (2025)**. **24 Provisionals and licensed 3 patent portfolios**. Products tested to national standards and independently validated.



Contact

Marc McConnaughey – CEO
BioBond Powered By Nature
6025 West 300 South
Lafayette, Indiana 47909
marc@biobondadhesives.com
1-909-631-9598





Executive Summary

\$6M at a \$30M Post-Money Valuation.

The Problem: Strategic & Environmental Chokepoints

The global transition to advanced electronics, electric vehicles, and national defense systems is paralyzed by a dual crisis:

- Mineral Sovereignty: 90% of refined rare earth elements (REEs) are controlled by foreign entities. Traditional mining requires multi-year permitting and billions in capital expenditure, leaving the domestic supply chain deeply vulnerable.
- The Waste Liability: U.S. utilities and industrial companies are burdened by billions of waste (Coal Fly Ash, E-Waste, and Red Mud). These materials are multi-billion-dollar hazardous liabilities currently leaching into the environment.

The Mission: Securing Domestic Sovereignty

C2RE is a technology licensing company transforming toxic waste into Rare Earth "artificial ore" through industrial remediation. We provide a multi-year year shortcut to a domestic supply chain, enabling a self-reliant American manufacturing base for defense, aerospace, and semiconductor industries.

The Technology: "Modular Biological Refineries"

C2RE is developing a proprietary, multi-stage bio-chemical platform that replaces extreme heat and toxic acids with natural biological processes. Our closed-loop model ensures we capture value at every link of production:

- Stage 1: "Pre flight Assay": Proprietary diagnostics "fingerprint" feedstock composition to algorithmically map microbial extraction parameters before processing. AI powered genetic control
- Stage 2: Bio-Leaching: Microbial (fungi/yeast) consortia in massive off the shelf fermentation tanks naturally secrete acids to strip metals into a liquid solution at near ambient temperatures.
- Stage 3: Precision Recovery: On-site, targeted chemical precipitation from bio-leaching fluid combined with waste (coal ash, ewaste, red mud, mine tailings) results in **Metal Salts** tailored perfectly to midstream separations buyer specifications.

The Market: Tri-Sector Universal Platform

C2RE is a universal engine driving three multi-billion-dollar markets:

- Coal Fly Ash (Utility & Environment): A volume-driven market anchored by federal EPA remediation mandates for legacy ash ponds.
- E-Waste (Technology & Urban Mining): A high-concentration market for the recovery of Gold, Silver, Palladium, etc. from printed circuit boards.
- Red Mud / Sludge (Defense & Semiconductors): A strategic market for Gallium and Scandium, essential for 5G/6G hardware, AI chips, and high-performance alloys.

Competitive Defense in Layers

- Economic Inversion: While traditional miners pay to dig, C2RE partners can be paid to take the feedstock via remediation fees, creating a structurally near-negative cost basis.
- Recipe Lock: Our microbial strains and batch-tuning data are proprietary data assets; competitors cannot replicate our yields without the C2RE biological "software". We scale the biology, not the machinery
- Speed to Market: By co-locating at existing brownfield sites using modular hardware, C2RE reaches operational status in months rather than a decade of mining red tape.

Use of Proceeds

- Use of \$6M Capital: 45% (\$2.7M) for Industrial Scale-Up to TRL 7; 30% (\$1.8M) for IP Portfolio & Recipe Optimization; 25% (\$1.5M) for Strategic BD & Regional Hub Partnerships.

EXECUTIVE SUMMARY




Get more out of your depression therapy...

VALUE PROPOSITION

Hedonia is a revolutionary product, an all-natural, first-of-its-kind medical food. It is specially formulated to address the unique nutritional needs of people suffering from depression, without the need for a prescription and without the side effect profile associated with pharmacological agents.

Hedonia® is not a drug. It is not a supplement. It is a unique patented 3-in-1 product classified as a medical food. Hedonia is specifically formulated to address the unique nutritional imbalances and or deficiencies of people with depression, which cannot be managed by an ordinary diet alone. The nutrients (Omega-3, SAME, and L-Methylfolate) occur naturally in your body but may be out of balance in your brain if you suffer from depression. Hedonia works by raising the levels of these critical nutrients to normal, healthy levels. Medical foods have been used since the 1950s. They have been developed for many diseases, such as Crohn's, ulcerative colitis, gastroesophageal reflux, insomnia, Alzheimer's, and Parkinson's. Examples of Medical foods include Pedialyte, Ensure, Glucerna, and Pulmocare.



LEADERSHIP TEAM

Alexander Vuckovic, M.D. Founder, Inventor & Chief Scientific Officer

Dany Sfeir, Chief Executive Officer

Gary Schwartz, Chief Financial Officer (*In Role*)

Bengt Persson, Global VP of Manufacturing and R&D

SCIENTIFIC BOARD OF ADVISORS

Alexander Vuckovic, MD Founder & CSO

Dr. Joseph Firth, PhD University of Manchester, United Kingdom

Derek Tobin, PhD Clinical Science Manger Epax, Norway

Prof. Jerome Sarris, PhD Psychae Institute, Australia

COMPANY BACKGROUND

Hedonia USA, Inc. was incorporated in January 2021 in the State of Delaware. The company was founded by Dr. Alex Vuckovic, a Harvard Medical School Psychiatrist and Pscopharmacologist, based upon his over 40 years of treating patients with depression as well as substantial published research by many practitioners.

COMPETITION



There has never been a product like Hedonia on the market and as we sit here today there is no competition. It is believed that we will not have a direct competition for a long time because of our patent protection and willingness to defend it.

DISTRIBUTION CHANNELS



We launched Hedonia in Q3 2024 and will initially be marketed as medical food and sold as direct to consumer (D2C) via our website. After the launch of the medical food product, we will add Hedonia to select retailers in while growing the DTC channel. Within 2 years we will execute our full retail strategy, working with pharmacies and large retailers to sell Hedonia both as a medical food and in alternate formulation with a family of supplements to address the 80 million USA residents who take supplements daily.

PATENTS



Hedonia has patents that protect the product through 2037 both domestically and internationally as well as in an supplement version. In addition, the company has a patent on its special dual capsule delivery system.



ADDRESSABLE MARKET

The World Health Organization (WHO) estimates there are one billion people globally suffering from depression, or about 1 in every 5 people. In the United States, 31 million people have mild to intermittent depression. At an average cost of \$2,200 for a one-year supply of Hedonia would be a \$6.82 billion in market just in the USA.

Rolling BUSINESS UPDATES (April 2026)

Hedonia is currently selling \$620K+ on [Hedonia.com](https://hedonia.com) with growing daily sales since December 2024. Subscription renewals is on the rise 60%+, cancelations are a mere single digit number and returns are a fraction of a percent.



ASK

Hedonia USA, Inc. has raised \$5.2 million to date both in seed capital and a Series A round. Currently, we are seeking up to \$20 million in financing. The capital will be used as follows:

Marketing & Media	52%
Manufacturing & Raw Material	22%
Talent Acquisition	11%
Research & Development	15%
Total	100%

TPlan0526V1.5A

ODNASS Early Cancer Screening System

Investor Executive Summary | Updated May 2026 | Seed SAFE US \$1.5M — US \$890K closed (59%) / US \$610K remaining

Odnass is transforming early cancer detection through **direct cfDNA quantification from plasma** — a rapid, affordable, scalable method using AI, Graph Neural Networks (GNN), and Blockchain — enabling **multi-cancer detection at the non-symptomatic stage**, with target TOT under 3 hours and target cost below US \$100/test.

Value Proposition

Blood-based multi-cancer screening that detects early neoplastic changes directly from plasma — no sequencing, no column extraction. Combines simplified cfDNA quantification with AI/GNN analytics and blockchain data security. Positioned as a **proof-first, partner-led diagnostics platform**; this raise underwrites measurable technical proof at Proof-of-Concept, not narrative scale.

Company Background

Australian-based MedTech/AI biotech. Provisional patent **AU 2025902937** filed July 2025. Laboratory and validation infrastructure established in EU; Proof-of-Concept activity underway in 2026.

Leadership Team

- Dr Velimir Pajic** — CEO & Co-Founder. Medical scientist (MBBS Belgrade; BSc Curtin; MIT xPRO; Judge Business School at the University of Cambridge). Clinical science, modelling, medtech commercialisation.
- Tadej Tofant** — CTO & Co-Founder. Data science, ML, instrument development; NATO-funded blood-based defence research; banking + medtech infrastructure.
- Dr Zeljko Perdija** — COO & Co-Founder. Internal medicine specialist (pulmonology, gastroenterology); Medical Director; lab workflow and platform deployment.
- Chris Rowe** — Strategic Advisor & Cornerstone Investor. Cambridge MA (Econ & Law); former Chairman ASX100 Northern Star Resources (2003–2016); 30+ years ASX board and capital markets.

Research & Technology

Direct cfDNA detection from plasma with AI/GNN-enhanced signal interpretation; minimal equipment; blockchain-secured data loop for auditability, provenance, integrity, and EMR (Electronic Medical Record) integration. The patent covers detection process, AI/GNN modelling, and a blockchain layer, creating defensible barriers to entry.

Market & Distribution

Global MCED market **>US \$150B** (CAGR >13%). Long-term target: up to 60M tests/year at ~US \$100/test (**~US \$6B revenue opportunity**). Model: IP licensing or strategic acquisition. Channels: Tier-1 MedTech partners (Roche, Guardant Health, Illumina, Exact Sciences) and diagnostic networks.

Competitive Landscape

Platform	Method	TAT	Price
Galleri (Grail)	ctDNA sequencing	10–14 days	~US \$950
Quadrant Shield	ctDNA + AI	7–10 days	~US \$1,200
OncoSeek	Protein biomarkers	3–5 days	~US \$145
Odnass (target)	Direct cfDNA + AI/GNN + BC	<3 hours	<US \$100

Odnass figures reflect internal modelling and early laboratory assumptions; performance to be confirmed at PoC.

External Review & Alignment

Independent US-based investment entity (Feb 2026) concluded Odnass is **financeable as a proof-first, partner-led diagnostics platform**. SAFE gated to four milestones: (1) Analytical Validation, (2) Clinical Feasibility, (3) Workflow Economics, (4) Partner Readiness.

Financial Projection (Indicative)

Scenario	Annual Tests	Revenue	Gross Margin
Global (full scale)	60 million	US \$6 Billion	>70%
Initial regional	6 million	US \$600 Million	>70%

Indicative long-term opportunity sizing; not a forecast.

OPERATIONAL READINESS

Proof-of-Concept underway. EU-based validated lab infrastructure, patent protection, and multi-disciplinary team. Positioned for partnership, licensing, and acquisition discussions at the PoC inflection point.

Why Odnass Is Unique

- Sequencing-free detection — reduces complexity and cost
- Scalable economics enabling population-level screening
- GNN-powered analytics for deeper biological signal interpretation
- Blockchain-secured data architecture for integrity and trust
- Designed for global healthcare deployment, including emerging markets
- Experienced founders across medtech, oncology, ML/GNN, and business development.

Redefining early cancer screening through rapid, accessible, AI-driven detection.

Quick Facts

Company: Odnass Pty Ltd
Contact: Dr Velimir Pajic, CEO
Address: Perth, WA, Australia
Email: velimir.p@odnass.com
Website: www.odnass.com
Industry: MedTech / Biotechnology
Patent: AU 2025902937 — cfDNA Detection + AI/GNN + Blockchain
Raise: US \$1.5M SAFE — \$890K closed (59%) / \$610K remaining
Use of Funds: PoC gates: Analytical Validation.

Overview: Founded in 2012, Wintermute Biomedical Inc. (WBI) has developed and patented a novel chemistry platform technology that can be used to create antibacterial, anti-viral, and anti-fungal water-soluble micelles from unsaturated and saturated fatty acids. This creates a broad-spectrum, stable solution for antimicrobial applications in medicine, industry, and agriculture.

Problem: Shingles is the latent reactivation of the Varicella Zoster Virus (VZV) in peripheral nerves that typically migrates to the skin causing extreme pain. Despite the availability of an effective shingles vaccine, the incidence of shingles continues to grow year over year.

- Due to cost and vaccine hesitancy, only 34.5% of adults over 60 are vaccinated in the United States (2018; CDC).
- Globally, 1 in 3 adults over 30 will suffer from shingles.
- Current standard of care is oral antivirals but they must be given within 3 days after onset of skin lesions or they are ineffective. Typically, this is difficult to achieve and they do not reduce pain.
- Opioids can be given for the pain but are largely ineffective and not normally prescribed due to addiction potential.
- There is a clear unmet need for a topical therapy for shingles that relieves pain quickly and enhances lesion healing.

Solution: WBI has invented and patented a shingles topical therapy, GS-1, for pain relief and enhanced lesion healing in shingles patients.

- It was FDA registered and has demonstrated excellent efficacy against VZV-infected skin.
- It has been tested on 100 human subjects with no skin reactions or sensitization.
- In a 30-patient double blind placebo, Solexan produced rapid pain reduction at the lesion site.

Market Analysis:

- There is a clear unmet need to develop a topical therapy to treat unvaccinated shingles patients to relieve pain. Nothing currently exists.
- An effective topical prescription therapy would generate an estimated \$550M-3B/yr for 16 years (patent lifespan).
- No effective treatment available

Traction:

- Successfully completed a phase Ib clinical trial in 30 shingles patients that clearly demonstrated excellent safety and robust pain relief in shingles patients.
- Currently negotiating a license agreement with two pharmaceutical companies to license post-phase II.
- Excellent team made up of leading experts in shingles, business development and regulatory affairs

Next Steps:

- WBI is seeking \$15M in equity funding to support a phase IIa double-blind placebo-controlled clinical trial in 220 patients for the topical treatment of shingles to assess pain relief and enhanced lesion healing.
- The trial will be managed in Australia to take advantage of the 43.5% cash rebate on research activities. The multi-site trial is ready to execute upon acquisition of funding and is scheduled for 18 months total.

SPEAKERS



TIEN WONG, CEO, OPUS8, INC.

Tien Wong is a private investor and technology entrepreneur focused on early- and growth-stage companies across life sciences, medtech, healthtech, and technology-enabled services. He is Chairman & CEO of Opus8, a capital strategy and investment firm that works with founders, boards, and investors on financing strategy, growth, and strategic positioning. Tien also serves as Executive Chairman of CONNECTpreneur and the New York Private Equity Forum, private capital platforms that convene accredited investors, family offices, and experienced operators around curated investment opportunities. Across these platforms, he has helped build one of the most active private investor communities in the Mid-Atlantic and Northeast. He is a Venture Partner with IronGate Capital Advisors and a member of the Investment Advisory Board of Virginia Venture Partners. Over his career, Tien has arranged or advised on capital from leading institutional investors, family offices, and strategic allocators worldwide.

PARTNERS



SHULMAN
ROGERS

NEXT powered by SHULMAN ROGERS

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior service across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at ShulmanRogers.com.



ANTHONY MILLIN, Founder and Co-Chair, NEXT powered by Shulman Rogers

Anthony Millin is a trusted legal and business advisor to startup and emerging growth companies. Anthony is a senior startup attorney, a serial entrepreneur, and a former venture partner in a seed stage VC fund. As the Founder and Co-Chair of NEXT powered by Shulman Rogers, selected by LegalWeek as a finalist the past three years and the 2024 winner as the nation's top law firm for "Enabling Startup Success", Anthony brings his unique legal and business perspective to advising his clients. Anthony is also the Co-Founder of My Next Raise, launched by NEXT, a technology, community and education platform providing founders with a pathway to investor readiness. Anthony was recently elected by his peers to serve on Shulman Rogers' Board of Directors. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund raising process, and to address the legal issues faced by a startup. This background provides him with valuable insights into the legal and business needs of his clients. A creative problem solver and strong advocate dedicated to the success of his clients, Anthony frequently serves as his clients' "outside general counsel, taking a leadership role in managing the full range of their legal needs from formation and financings to growth and exit. Anthony is a frequent public speaker on topics impacting startup and emerging growth companies.



REFRACTION

Refraction is a leading nonprofit innovation hub in Northern Virginia, that provides mentoring, programs, and office space for startups and high-growth companies to help create jobs in the greater Washington region. In five years, more than 300 member companies have collectively raised over \$350 million in capital. Refraction's partners include Amazon, Cox, Dominion Energy, MITRE, Fairfax County, Arlington County, Loudoun County, Virginia Innovation Partnership Corporation, and Virginia Tech.



NFP

NFP is a leading insurance broker and consultant that cares deeply about our employees' and clients' well-being. We're honest, hardworking, dedicated professionals who love what we do and strive to lead by example. But what truly defines us is that for us, business is personal. At the end of the day, our vision isn't a financial metric or a top 10 list. It's that when you hear "NFP," you think of a world-class company that's authentic, genuine and real. One whose expertise and scale are only matched by its passion for building lifelong personal relationships.

PARTNERS



DINGMAN CENTER FOR ENTREPRENEURSHIP, UNIVERSITY OF MARYLAND

The Dingman Center for Entrepreneurship is a top-tier entrepreneurial institute recognized around the world as a leader in enterprise creation. The Dingman Center is continuously pushing the boundaries of teaching and learning with its focus on practical entrepreneurship, global innovation, and international classroom experiences. The Center promotes opportunities that provide maximum resources to start-up businesses in terms of ideation, execution, and financing; and that support its mission to take entrepreneurs “from the back of a napkin to the first \$1 million in financing.”



KEIRETSU FORUM

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 53 chapters on 3 continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities.



FITCI - FREDERICK INNOVATIVE TECHNOLOGY CENTER, INC

The Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. FITCI specializes in the strategic business support of local entrepreneurs in the early stages of mostly science and technology-based businesses: Biotechnology, Information Technology, Renewable Energy, and Cyber Security. FITCI currently has two locations in Fredrick, MD, and 52 client companies.



MARYLAND TECH COUNCIL VENTURE MENTORING SERVICES

The Maryland Tech Council Venture Mentoring Services (MTC VMS) program is one of the leading team mentoring services available in the state of Maryland that is both highly sophisticated and results-driven. It exists to foster an environment that encourages innovation while expanding financial and business opportunities for tech, cyber, and life science start-ups. The MTC VMS Program provides free team-based mentoring services to qualified Maryland-based tech and life science venture CEOs who are accepted into the program. Since the MTC VMS program began, more than 75 ventures have enrolled & \$100MM has been raised in capital & grants.



STARTUP GRIND-COLUMBIA, MD

Startup Grind-Columbia, mid-Maryland Chapter is part of the largest global community for innovation, entrepreneurship, and the startup community. We're actively educating, inspiring, and connecting more than 2MM+entrepreneurs, 600+ cities, and 130+ countries. We nurture startup ecosystems through mentorship, advisory services, education, inspiration, access to capital, and most importantly, connecting members with the resources we need to have the best opportunity to grow phenomenally successful ventures.

PARTNERS

Angels + Life.Sci Investors

ANGELS + LIFE.SCI INVESTORS

Formed in 1996, the Angels + Life.Sci Investors Network is organized under NJAngels.net. We are a manager-led, loosely organized network of investors and accredited Angels, Coaches, and Experts who Sponsor world-class Entrepreneurs. Our colleagues have deep experience and technical domain expertise in all of the life sciences disciplines in which we are involved, including nanobio tools, materials, and devices: tele-diagnostics, augmented healthcare & remote patient monitoring, automation and robotics, & advanced chemistry for drug discovery.



GEORGETOWN ENTREPRENEURSHIP INITIATIVE

Entrepreneurship is one of the world's most powerful forces for positive change. Georgetown Entrepreneurship seeks to instill an entrepreneurial mindset in students, foster an entrepreneurial culture across the university, support the successful growth of alumni ventures, and leverage the power of entrepreneurship to make an impact in the world beyond Georgetown.



RYAN & WETMORE, P.C

Ryan & Wetmore is a full-service accounting and management consulting firm, servicing the Northeast/ Mid-Atlantic region since 1988. What makes us different from other accounting firms is our proactive approach. We work hard to earn our clients' confidence by encouraging open communication year-round. This approach has enabled us to help clients become more efficient, more competitive, and more profitable. Through our numerous management engagements, we have become trusted, unbiased advisors.



PETE RYAN, CO-FOUNDER & PARTNER, RYAN & WETMORE

Pete co-founded Ryan & Wetmore in 1988, a 3 office, 35-person firm serving the Mid-Atlantic region. He currently works with clients to address tax, audit, and accounting issues. He also has significant experience in international tax matters and business consulting services. His expertise extends to Healthcare organizations, Construction and Real Estate, Government contractors, Technology, Manufacturing, and High Net Worth Individuals. Pete has served on the Board of Directors for several organizations. He is an active member of the Healthcare Advisors Association, the Real Estate and Construction Association, the CPA Manufacturing Services Association, the Virginia Transportation Construction Alliance, and the Construction Financial Management Association.



ENTERPRISE TRANSFORMATION SOLUTIONS

INES LEBOW, FOUNDER AND PRINCIPAL

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.



THANK YOU TO OUR PREP TEAM



MICHAEL HANSON
Consultant
Optimum Dynamics LLC



LAURA HILL
Chief of Staff
Bentley



INES LEBOW
CEO
Enterprise Transformation
Solutions



MARISSA LEVIN
CEO
Successful Culture
International



JET LU
Customer Solutions
Amazon Web Services



JACKIE LUO
Founder
BAM Advisory



MICHELLE MILLER
Founder
MRM Consulting



JOHN MORGAN
General Partner
Morgan Global



EVAN SHUBIN
Pres. and Founder
Results.now, Inc. and
Candlelight Partners



MALI PHONPADITH
CEO
SOAR Community
Network



MICHAEL RIEMER
CEO & Board Member
Vocinity

SPONSORS



CONNECT with us!



Register for our upcoming events

In-Person Event

June 4
Tysons Corner, VA



Investor Reception

June 22
San Diego, CA



In-Person Event

September 23
Washington, DC

